Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Journal:

Journal of the American Academy of Dermatology

Published:

2025-05-17

DOI:

10.1016/j.jaad.2025.05.1391

Affiliations:

14

Authors:

14

Go to article

Institutions	Authors	Share
Dermavant Sciences, Inc., United States of America (USA)	2.000000	0.17
The George Washington University (GW), United States of America (USA)	1.000000	0.08
Weill Cornell Medicine, United States of America (USA)	1.000000	0.08
Innovaderm Research Inc., Canada	1.000000	0.08
Texas Dermatology, United States of America (USA)	1.000000	0.08
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.08
Oregon Health and Science University (OHSU), United States of America (USA)	1.000000	0.08
Henry Ford Health System (HFHS), United States of America (USA)	1.000000	0.08
AllerVie Health – Homewood, United States of America (USA)	1.000000	0.08
Rady Children's Hospital-San Diego, United States of America (USA)	0.500000	0.04
University of California, San Diego (UC San Diego), United States of America (USA)	0.500000	0.04
The University of Texas Health Science Center at Houston (UTHealth), United States of America (USA)	0.500000	0.04
Children's Memorial Hermann Hospital, United States of America (USA)	0.500000	0.04

Interested in Clinical Sciences?